1 / 35

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis. Activity Goals. Prognosis: CALR MF is a Distinct Entity. Clinical Effect of Founding Driver Mutations in MF. Phase 1b: Panobinostat and Ruxolitinib in MF. Novel Combination: PRM-151 + RUX. ET: Molecular Markers.

lyle-bates
Download Presentation

Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pivotal Data Highlights on Myeloproliferative NeoplasmsMyelofibrosis

  2. Activity Goals

  3. Prognosis: CALR MF is a Distinct Entity

  4. Clinical Effect of Founding Driver Mutations in MF

  5. Phase 1b: Panobinostat and Ruxolitinib in MF

  6. Novel Combination: PRM-151 + RUX

  7. ET: Molecular Markers

  8. ET: Impact of Treatment on Molecular Markers

  9. Prognosis and Risk Stratification

  10. Splanchnic Vein Thrombosis

  11. Pivotal Data Highlights on Acute Myeloid LeukemiaFLT3 Inhibition

  12. Phase 2: Efficacy of Quizartinibin Relapsed/ Refractory AML

  13. Quizartinib as a Bridge to HCT in FLT3-ITD(+) AML

  14. Pivotal Data Highlights on Acute Myeloid LeukemiaNew Agents for Older Patients

  15. Phase I/2 Study of Volasertib

  16. Phase 2:Efficacy and Safety of SGI-110

  17. Abbreviations

  18. Abbreviations (cont)

  19. Abbreviations (cont)

  20. References

  21. References (cont)

  22. References (cont)

  23. References (cont)

  24. References (cont)

  25. References (cont)

  26. References (cont)

  27. References (cont)

  28. References (cont)

  29. References (cont)

More Related